ZNTL
Zentalis Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $250M market cap
Forecast run · Sep 14, 2026Upside rank 596 of 3,136
Model Signal
ForecastQ Daily Probabilities
53.4%
29.4%
39.6%
Analyst Consensus
Recommendation2.33/5 Buy
Last price$3.51
Price target$8.33
Implied move+137.3%
Analysts12
ForecastQ Portfolios
ZNTL is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.